Arginine supplementation in children with sickle cell crisis

Cardiovascular changes in sickle cell crisis and impact of arginine supplementation in vaso-occlusive crisis and acute chest syndrome

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201611001864290

Enrollment

100

Registered

2016-11-12

Start date

2016-12-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Haematological Disorders Paediatrics Sickle cell disease

Interventions

Arginine supplementation

Placebo-galactose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Presence of HbSS Painful crisis with pain score of 7 and above Acute chest syndrome

Exclusion criteria

Exclusion criteria: Allergy to arginine Hb concentration of 5g/dl and below Presence of congenital and acquired heart diseases Electrolyte derangement Patients with kidney and liver diseases

Design outcomes

Primary

Measure	Time frame
proportion of children with myocardial ischaemia, percentage change in mean Doppler estimated pulmonary artery pressure and percent reduction in total analgesic medications	—

Secondary

Measure	Time frame
1. Changes in cardiac biomakers. 2. Changes in wall stress and ventricular functions. 3. Mean changes in Doppler estimated mean pulmonary artery pressure. 4. Changes in pain scores. 5. Time of crisis resolution. 6. Time from initiation of arginine supplementation to the last dose of parenteral analgesia	—

Countries

Nigeria

Contacts

Public ContactRichard Onalo

Consultant Paediatrician

richardonalo@yahoo.com+234 803 701 7678

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026